GleamWall
中文EN

SHPH Shuttle Pharmaceuticals Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1757499 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY15.5%
TTM EPS YoY158.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-90.1%
ROA-72.5%
ROIC (approx.)-99.2%
Asset turnover—

Leverage & solvency

Liabilities / assets15.9%
Debt / equity0.00x
Current ratio0.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-26.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue————————
R&D expense$55,661$267,240$511,878$943,478$1.03M$1.57M$986,409$1.40M
SG&A expense$1.98M$1.16M$1.84M$886,055$2.35M$596,886$429,067$328,995
Operating income-$3.95M-$2.22M-$2.79M-$2.27M-$3.91M-$2.95M-$1.78M-$3.05M
Net income-$3.15M-$2.15M-$2.61M-$2.35M-$3.71M-$3.05M-$1.60M-$3.78M
EBITDA-$3.32M-$1.58M-$2.50M-$2.27M-$3.91M-$2.95M-$1.78M-$3.05M
EPS (basic)-3.10-0.43—-1.05-32.91-7.60—-39.83
EPS (diluted)-3.10-0.43—-1.05-32.91-7.60—-39.83
Weighted avg. shares (diluted)1.02M5.03M—2.23M112,611401,957—95,004
Balance sheet
Cash & equivalents$90,238$1.09M$334,005$2.09M$4.82M$4.51M$1.92M$156,656
Current assets$396,353$2.46M$502,911$3.27M$5.19M$4.96M$2.21M$361,351
PP&E, net$15,191$16,311$17,319$18,327$19,335$18,356$19,364$21,160
Intangibles$8.65M$9.24M$9.84M—————
Total assets$22.81M$11.81M$10.48M$3.54M$5.50M$5.31M$2.51M$673,568
Current liabilities$3.48M$8.31M$7.97M$1.96M$1.69M$1.78M$1.53M$1.66M
Total liabilities$3.63M$8.46M$8.22M$2.15M$1.90M$2.02M$1.80M$1.99M
Shareholders' equity$19.18M$3.35M$2.25M$1.39M$3.61M$3.29M$709,152-$1.32M
Shares outstanding1.00M5.55M202,3621.24M1.07M6.38M163,0932.95M
Cash flow statement
Operating cash flow-$567,640-$2.42M-$973,012-$2.63M-$3.36M-$2.53M-$2.69M-$2.00M
Investing cash flow-$5.43M-$36,000————$0$1.66M
Financing cash flow$5.00M$3.21M$2.27M-$96,375$3.66M$5.12M$4.45M-$196,790
Depreciation & amortization$633,451$633,340$289,070$1,008-$979$1,008$1,796$793
Stock-based compensation-$7,511$35,018$214,750$134,318$46,853$537,046$31,858$45,275

Free plan shows the latest 8 periods; Pro shows all 22 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.